Palvella Therapeutics (PVLA) Cash from Financing Activities (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Cash from Financing Activities data on file, last reported at $214.7 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $214.7 million, up 17964.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $215.3 million (up 150.65% YoY), and the FY2025 annual result was -$660000.0, down 100.76% from the prior year.
• Cash from Financing Activities climbed to $214.7 million in Q1 2026 per PVLA's latest filing, from -$49000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $214.7 million in Q1 2026 and troughed at -$14.8 million in Q4 2023.
• A 5-year average of $22.4 million and a median of $315500.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities sank 15993.55% in 2023, then soared 17964.48% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $93000.0 in 2022, then slumped by 15993.55% to -$14.8 million in 2023, then soared by 605.95% to $74.8 million in 2024, then slumped by 100.07% to -$49000.0 in 2025, then surged by 438326.53% to $214.7 million in 2026.
• Business Quant data shows PVLA's Cash from Financing Activities at $214.7 million in Q1 2026, -$49000.0 in Q4 2025, and $242000.0 in Q3 2025.